UNS unilife corporation

why biotechs need to worry about generics, too, page-4

  1. 1,875 Posts.
    lightbulb Created with Sketch. 16
    well reason gabbie. Why then would the pharma pay a premium for allegly prolonging the life of the patent?
    Is that why the sp is heading down?
    The only thing then uns has for their product is the safety issue. Cost then would be a big factor contributing to the take up.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.